Effects of Angiotensin-Converting Enzyme Inhibition and Angiotensin II Type 1 Receptor Blockade on β-Adrenoceptor Signaling in Heart Failure Produced by Myocardial Infarction in Rabbits: Reversal of Altered Expression of β-Adrenoceptor Kinase and Giα
- 1 January 2003
- journal article
- Published by Elsevier in The Journal of Pharmacology and Experimental Therapeutics
- Vol. 304 (1) , 370-379
- https://doi.org/10.1124/jpet.102.040956
Abstract
Both angiotensin-converting enzyme (ACE) inhibitors and angiotensin II type 1 (AT1) receptor blockers have been demonstrated to improve symptoms and prognosis in heart failure (HF). We compared the effects of ACE inhibition and AT1 receptor blockade on myocardial β-adrenoceptor desensitization in rabbits with HF established 3 weeks after myocardial infarction (MI) with left circumflex coronary artery ligation. Rabbits with MI were randomized to no treatment, the ACE inhibitor temocapril (0.5 mg/kg/day) or AT1 receptor blocker valsartan (3 mg/kg/day). Echocardiographic examinations showed that, relative to rabbits with untreated MI, rabbits receiving temocapril or valsartan had a limitation of cardiac remodeling and prevention of the development of systolic dysfunction. Circulating plasma norepinephrine levels that were markedly elevated in MI animals were strongly inhibited by temocapril or valsartan therapy. β-Adrenoceptor density, β-adrenoceptor proportion showing high-affinity agonist binding, and basal and isoproterenol-stimulated adenylate cyclase activities were significantly reduced in MI rabbits. These defects were similarly reversed by temocapril or valsartan. Importantly, as found in human HF, myocardial protein levels of β-adrenoceptor kinase 1 and Giα were significantly elevated in MI rabbits, suggesting that these molecules are contributing to the defects in myocardial β-adrenoceptor signaling. The expression levels of these molecules were normalized equally by both treatments. The results suggest that pharmacologically different interventions in the renin-angiotensin system can equivalently improve the derangements in the β-adrenoceptor signaling system in the failing heart. This may be important for the beneficial effects of these agents in HF.Keywords
This publication has 37 references indexed in Scilit:
- A Randomized Trial of the Angiotensin-Receptor Blocker Valsartan in Chronic Heart FailureNew England Journal of Medicine, 2001
- BRADYKININ AND CARDIOPROTECTION: DON'T SET YOUR HEART ON ITPharmacological Research, 1997
- Signal transduction mechanisms controlling cardiac contractility and their alterations in chronic heart failureCardiovascular Research, 1995
- Prejunctional angiotensin II receptors. Facilitation of norepinephrine release in the human forearm.Journal of Clinical Investigation, 1994
- Pharmacological profile of valsartan: a potent, orally active, nonpeptide antagonist of the angiotensin II AT1‐receptor subtypeBritish Journal of Pharmacology, 1993
- Lisinopril lowers cardiac adrenergic drive and increases beta-receptor density in the failing human heart.Circulation, 1993
- Increased messenger RNA level of the inhibitory G protein alpha subunit Gi alpha-2 in human end-stage heart failure.Circulation Research, 1992
- Increase of the 40,000-mol wt pertussis toxin substrate (G protein) in the failing human heart.Journal of Clinical Investigation, 1988
- Beta 1- and beta 2-adrenergic-receptor subpopulations in nonfailing and failing human ventricular myocardium: coupling of both receptor subtypes to muscle contraction and selective beta 1-receptor down-regulation in heart failure.Circulation Research, 1986
- Decreased Catecholamine Sensitivity and β-Adrenergic-Receptor Density in Failing Human HeartsNew England Journal of Medicine, 1982